Clinical Trial Update: Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial assessed the effect of osimertinib (AZD9291) on rosuvastatin blood levels in patients with EGFR-mutant non-small cell lung cancer; results of th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AZD9291 (osimertinib)
• Rosuvastatin (rosuvastatin)

Snippet

Sponsor: AstraZeneca | Conditions: Non Small Cell Lung Cancer | Phase 1 | Status: COMPLETED | Results posted: 2016-07-14